Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Gilead Sciences Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale increased by 56.5% to $36.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale shows a downward trend with a -70.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher values indicate a high volume of maturing debt, providing liquidity for reinvestment or capital return.
Detailed definition
Cash inflows generated when debt securities held in the investment portfolio reach their maturity date, are called by th...
Peer comparison
Standard for insurance companies with large fixed-income portfolios to match long-term liabilities.
investing_proceeds_from_maturities_prepayments_and_calls_bc784fHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $631.00M | $558.00M | $372.00M | $506.00M | $449.00M | $277.00M | $358.00M | $324.00M | $395.00M | $266.00M | $349.00M | $327.00M | $0.00 | $15.00M | $17.00M | $23.00M | $36.00M |
| QoQ Change | — | -11.6% | -33.3% | +36.0% | -11.3% | -38.3% | +29.2% | -9.5% | +21.9% | -32.7% | +31.2% | -6.3% | -100.0% | — | +13.3% | +35.3% | +56.5% |
| YoY Change | — | — | — | — | -28.8% | -50.4% | -3.8% | -36.0% | -12.0% | -4.0% | -2.5% | +0.9% | -100.0% | — | — | — | — |
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Gilead Sciences (GILD) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $36.00M in Q1 2026.
- What is the long-term trend for Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 3 years (2021 to 2025), Gilead Sciences's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -70.7% compound annual growth rate (CAGR), from $2.18B to $55.00M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- Cash received from debt investments that have matured or been called.